In this article, Roswitha examines why less than 0.5% of healthcare VC reaches women's health and how funding structure shapes femtech validation rigor and investor trust.

What does it mean to build femtech that works for every woman?

A framework for inclusive validation, algorithmic fairness, and evidence-based reproductive health technology.

Roswitha Verwer on why femtech keeps failing the women who need it most, and what human-centered, culturally responsive co-design actually requires to change that.

Discover why an ethical, connected, and privacy-preserving data infrastructure is essential for building trust in FemTech and women’s reproductive healthcare.

Roswitha Verwer explores whether the term FemTech helps or limits women’s healthcare, and why the future must move beyond visibility toward full integration in mainstream medicine.

Roswtha Verwer explores how delayed diagnosis in reproductive health drives emotional, financial, and clinical costs, and how earlier biological insight can reduce failed fertility cycles and unnecessary escalation.

Roswitha Verwer shares why YON E is closing its seed readiness round, how funding will support prototype completion, clinical trial preparation, regulatory readiness, and the next phase of women’s health diagnostics.